Wells Fargo & Company Theravance Biopharma, Inc. Transaction History

Wells Fargo & Company

$507 Billion
Q3 2025

A detailed history of Wells Fargo & Company transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 24,753 shares of TBPH stock, worth $430,454. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,753

Previous 20,495 20.78%

Holding current value

$430,454

Previous $226,000 59.73%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$10.9 - $14.6 $46,412 - $62,166	4,258 Added 20.78%	24,753 $361,000
Q2 2025 Aug 14, 2025	SELL	$8.32 - $11.25 $16,132 - $21,813	-1,939 Reduced 8.64%	20,495 $226,000
Q1 2025 May 13, 2025	BUY	$8.44 - $10.47 $6,161 - $7,643	730 Added 3.36%	22,434 $200,000
Q4 2024 Feb 12, 2025	BUY	$7.93 - $10.08 $37,231 - $47,325	4,695 Added 27.6%	21,704 $204,000
Q3 2024 Nov 13, 2024	BUY	$7.66 - $10.25 $5,538 - $7,410	723 Added 4.44%	17,009 $137,000

Q2 2024 Aug 13, 2024	SELL	$8.29 - $9.92 $12,965 - $15,514	-1,564 Reduced 8.76%	16,286 $138,000
Q1 2024 May 10, 2024	BUY	$8.22 - $11.59 $10,390 - $14,649	1,264 Added 7.62%	17,850 $160,000
Q4 2023 Feb 09, 2024	BUY	$8.58 - $11.4 $14,105 - $18,741	1,644 Added 11.0%	16,586 $186,000
Q3 2023 Nov 13, 2023	SELL	$8.38 - $10.44 $79,325 - $98,825	-9,466 Reduced 38.78%	14,942 $128,000
Q2 2023 Aug 15, 2023	BUY	$10.16 - $11.92 $111,028 - $130,261	10,928 Added 81.07%	24,408 $252,000
Q1 2023 May 12, 2023	BUY	$9.87 - $11.44 $122,950 - $142,508	12,457 Added 1217.69%	13,480 $146,000
Q4 2022 Feb 13, 2023	SELL	$9.65 - $11.34 $9,640 - $11,328	-999 Reduced 49.41%	1,023 $11,000
Q3 2022 Nov 14, 2022	SELL	$8.39 - $10.22 $4,908 - $5,978	-585 Reduced 22.44%	2,022 $21,000
Q2 2022 Aug 12, 2022	SELL	$8.41 - $10.34 $40,662 - $49,993	-4,835 Reduced 64.97%	2,607 $24,000
Q1 2022 May 16, 2022	SELL	$8.33 - $12.96 $188,774 - $293,699	-22,662 Reduced 75.28%	7,442 $71,000
Q4 2021 Feb 14, 2022	BUY	$7.42 - $11.05 $108,665 - $161,827	14,645 Added 94.73%	30,104 $334,000
Q3 2021 Nov 15, 2021	SELL	$6.77 - $14.41 $1.18 Million - $2.51 Million	-173,886 Reduced 91.84%	15,459 $114,000
Q2 2021 Aug 16, 2021	BUY	$14.52 - $22.46 $94,089 - $145,540	6,480 Added 3.54%	189,345 $2.75 Million
Q1 2021 May 13, 2021	SELL	$16.57 - $21.08 $1.48 Million - $1.88 Million	-89,297 Reduced 32.81%	182,865 $3.73 Million
Q4 2020 Feb 09, 2021	SELL	$14.89 - $20.16 $68,851 - $93,219	-4,624 Reduced 1.67%	272,162 $4.84 Million
Q3 2020 Nov 05, 2020	SELL	$14.79 - $22.49 $63,789 - $96,999	-4,313 Reduced 1.53%	276,786 $4.09 Million
Q2 2020 Aug 13, 2020	BUY	$20.64 - $30.69 $1.68 Million - $2.49 Million	81,190 Added 40.61%	281,099 $5.9 Million
Q1 2020 May 14, 2020	BUY	$17.84 - $31.21 $3.57 Million - $6.24 Million	199,909 New	199,909 $4.62 Million

Others Institutions Holding TBPH

# of Institutions

171

Shares Held

50.5M

Call Options Held

36.5K

Put Options Held

147K

View Full List

About Theravance Biopharma, Inc.

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $1.16B
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

More about TBPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Theravance Biopharma, Inc. Transaction History